Literature DB >> 8216850

Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization.

M D Eisenbraun1, D H Fuller, J R Haynes.   

Abstract

A human growth hormone expression construct was delivered intracellularly into the abdominal skin of mice by particle bombardment-mediated gene transfer. Using this technology, the in vivo delivery of antigen-encoding expression vectors affixed to gold microprojectiles results in de novo antigen production in target skin and development of specific antibody responses. In this study, we examined the contribution of various delivery parameters to the resultant protein expression and related antibody responses. The highest levels of both protein expression and antibody production were correlated with particle delivery to the epidermis while deliveries extending into the dermis resulted in decreased protein and antibody production. Optimal immune responses were also shown to be dependent upon the delivery of a sufficient number of DNA-coated gold particles, indicating that a dose-response relationship exists between the number of particles delivered and the resultant protein expression and antibody production. Further, maximal protein expression and associated antibody titers were elicited with surprisingly small amounts of DNA. The practicality of targeting skin and the use of three to four orders of magnitude less DNA than is typically required in direct DNA inoculation studies demonstrates the potential utility of this emerging technology for the rapid production of antibodies in laboratory animals, and in the development of a new class of human clinical vaccines based upon direct, intracellular DNA delivery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216850     DOI: 10.1089/dna.1993.12.791

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  36 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  A differential proteome in tumors suppressed by an adenovirus-based skin patch vaccine encoding human carcinoembryonic antigen.

Authors:  Chun-Ming Huang; Zhongkai Shi; Tivanka S DeSilva; Masato Yamamoto; Kent R Van Kampen; Craig A Elmets; De-chu C Tang
Journal:  Proteomics       Date:  2005-03       Impact factor: 3.984

3.  Quantitative analysis of the immunopotency of genetically transfected dendritic cells.

Authors:  L Timares; A Takashima; S A Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

4.  Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1.

Authors:  Y Lu; K Q Xin; K Hamajima; T Tsuji; I Aoki; J Yang; S Sasaki; J Fukushima; T Yoshimura; S Toda; E Okada; K Okuda
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

5.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 6.  Drug delivery issues in vaccine development.

Authors:  M F Powell
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

7.  Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues.

Authors:  Olle Bjorkdahl; Karen A Barber; Sara J Brett; Maria G Daly; Christopher Plumpton; Nabil A Elshourbagy; John P Tite; Lindy L Thomsen
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice.

Authors:  S Kodihalli; H Goto; D L Kobasa; S Krauss; Y Kawaoka; R G Webster
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.